Kyle Guterba
Psychiatric/Mental Health · Austintown, OHNPI 1093239717
Payments from drug & device makers
Across 868 payments — averaging $81.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$35K
- AbbVie$27K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$1K
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$910
- plus $4K from 21 others
What the payments were for
- Consulting fees$17,38825%
- Speaking & faculty fees$32,03845%
- Travel & lodging$5,7668%
- Food & beverage$15,04021%
- Education$2030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 97 | $34,637 |
| AbbVie(2 entities) | 252 | $27,028 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,365 |
| Teva Pharmaceuticals USA, Inc. | 109 | $1,206 |
| Lundbeck LLC | 105 | $1,057 |
| Otsuka America Pharmaceutical, Inc. | 45 | $910 |
| Alkermes, Inc. | 32 | $840 |
| Neurocrine Biosciences, Inc. | 26 | $557 |
| Vanda Pharmaceuticals Inc. | 24 | $504 |
| Johnson & Johnson | 16 | $376 |
| E.r. Squibb & Sons, L.L.C. | 14 | $334 |
| Corium, LLC | 22 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $236 |
| Eisai Inc. | 13 | $199 |
| Supernus Pharmaceuticals, Inc. | 15 | $189 |
| Almatica Pharma LLC | 10 | $157 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $113 |
| Sanofi | 1 | $107 |
| Neos Therapeutics, LP | 3 | $58 |
| Merck | 4 | $55 |
| Avanir Pharmaceuticals, Inc. | 3 | $44 |
| Noven Therapeutics, LLC | 3 | $42 |
| Validus Pharmaceuticals LLC | 2 | $38 |
| Adlon Therapeutics L.p. | 1 | $21 |
| Noven Pharmaceuticals, Inc. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$70,434 in reported general payments places this provider in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 125 | $179,937 |
| AristadaAripiprazole Lauroxil | 23 | $72,576 |
| CaplytaLumateperone Tosylate | 35 | $62,776 |
| Invega SustennaPaliperidone Palmitate | 17 | $43,369 |
| AuvelityDextromethorphan Hbr/Bupropion | 27 | $30,363 |
| RexultiBrexpiprazole | 12 | $23,086 |
| BelsomraSuvorexant | 29 | $13,584 |
| TrintellixVortioxetine Hydrobromide | 22 | $10,909 |
| Lurasidone Hcl | 37 | $6,929 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 66 | $1,734 |
| Duloxetine Hcl | 106 | $1,490 |
| Paliperidone ErPaliperidone | 11 | $1,043 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 12 | $997 |
| Oxcarbazepine | 31 | $994 |
| Bupropion XlBupropion Hcl | 72 | $933 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $27,028 | $179,937125 claims |
| Alkermes, Inc.Aristada | $840 | $72,57623 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,365 | $62,77635 claims |
| Johnson & JohnsonInvega Sustenna | $376 | $43,36917 claims |
| Axsome Therapeutics, Inc.Auvelity | $34,637 | $30,36327 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $910 | $23,08612 claims |
| MerckBelsomra | $55 | $13,58429 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $236 | $10,90922 claims |
| Almatica Pharma LLCSertraline Hcl | $157 | $41572 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,808 psychiatric/mental health providers in Ohio.
Other psychiatric/mental health in Austintown
- Diana IsaacsAustintown$52K
- Crystal TravisJackson$333K
- Kristina RoweIronton$253K
- Patricia SparksPortsmouth$210K
- Mary HallWarren$195K
- Kassandra KornbauCanfield$170K
- Terri PopovitzCincinnati$161K
- Steven MatesDayton$121K
- Robert ParsonsYoungstown$119K
- Chriscia BaneChillicothe$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.